By varying the physical properties of collagen, investigators found that MDA-MB-231 tumor cells invaded and escaped faster in lower-density ECM. These effects were mediated by the ECM pore size, rather than by the elastic modulus or interstitial flow speed.
6630899 ICS6DYPG items 1 apa default asc 1
Despite several efforts, transcriptomic and genomic classifications have remained merely theoretic and most of the patients are being treated with chemotherapy. Driver alterations in potentially targetable genes, including PIK3CA and AKT, have been identified across triple negative breast cancer subtypes, prompting the implementation of biomarker-driven therapeutic approaches.
[npj breast cancer]
6445212 UTL7INB7 items 1 apa default asc 1
Investigators found that active targeting nanoparticles displayed a superior DNA damage capability via enhanced-interactions with DNA and a significantly stronger effect in reducing cancer stem cell-like property of triple negative breast cancer cells, compared to conventional cisplatin and miriplatin.
[Journal of Controlled Release]
6445212 W89EEME9 items 1 apa default asc 1
Li, Y., Qian, D., Lin, H.-P., Xie, J., Yang, P., Maddy, D., Xiao, Y., Huang, X., Wang, Z., & Yang, C. (2020). Nanoparticle-delivered miriplatin ultrasmall dots suppress triple negative breast cancer lung metastasis by targeting circulating tumor cells. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2020.10.015 Cite
By performing a mouse-human cross species analysis between the TAp63 metastatic mammary adenocarcinoma mouse model and models of human breast cancer progression, researchers identified two TAp63-regulated oncogenic lncRNAs, TROLL-2 and TROLL-3.
6807162 AUF2HCMS items 1 apa default asc 1
Napoli, M., Li, X., Ackerman, H. D., Deshpande, A. A., Barannikov, I., Pisegna, M. A., Bedrosian, I., Mitsch, J., Quinlan, P., Thompson, A., Rajapakshe, K., Coarfa, C., Gunaratne, P. H., Marchion, D. C., Magliocco, A. M., Tsai, K. Y., & Flores, E. R. (2020). Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation. Nature Communications, 11(1), 5156. https://doi.org/10.1038/s41467-020-18973-w Cite
The authors discuss novel bispecific antibodies for TNBC and emerging TNBC targets for future bispecific antibody development.
[Trends in Cancer]
Investigators highlight various models of lymphatic metastasis, their potential pitfalls, and other tools available to study lymphatic metastasis including imaging modalities and -omic studies.
[Journal of Mammary Gland Biology and Neoplasia]
Scientists demonstrated that the expression of FOXC1 was associated with resistance of doxorubicin treatment of breast cancer cells.
[Acta Pharmacologica Sinica]
Interruption of the Oxidative stress-responsive kinase 1 (OSR1)-Smad2/3-TGF-β1 signaling axis elicited a robust anti-EMT and anti-metastatic effect in vitro and in vivo.
Factor that binds to the inducer of short transcripts‐1 (FBI-1) enhanced the resistance of TNBC cells to chemotherapeutic agents by repressing the expression of micoRNA-30c targeting the pregnane X receptor (PXR).
[Cell Death & Disease]
6807162 5W4QVX55 items 1 apa default asc 1
Yang, H., Ren, L., Wang, Y., Bi, X., Li, X., Wen, M., Zhang, Q., Yang, Y., Jia, Y., Li, Y., Zang, A., Wei, Y., & Dai, G. (2020). FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis. Cell Death & Disease, 11(10), 1–14. https://doi.org/10.1038/s41419-020-03053-0 Cite
Investigators elucidated the potential role of a novel lncRNA FGF14-AS2 and the mechanisms underlying metastasis in breast cancer.
[Cell Death Discovery]
6807162 PNK4DZ98 items 1 apa default asc 1
Jin, Y., Zhang, M., Duan, R., Yang, J., Yang, Y., Wang, J., Jiang, C., Yao, B., Li, L., Yuan, H., Zha, X., & Ma, C. (2020). Long noncoding RNA FGF14-AS2 inhibits breast cancer metastasis by regulating the miR-370-3p/FGF14 axis. Cell Death Discovery, 6(1), 1–14. https://doi.org/10.1038/s41420-020-00334-7 Cite
Researchers probed the importance of O-GlcNAc transferase activity for the survival of tamoxifen-sensitive and tamoxifen-resistant breast cancer cells.
6807162 MCFF2VGV items 1 apa default asc 1
Barkovskaya, A., Seip, K., Prasmickaite, L., Mills, I. G., Moestue, S. A., & Itkonen, H. M. (2020). Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cells. Scientific Reports, 10(1), 16992. https://doi.org/10.1038/s41598-020-74083-z Cite